CSF3 and myeloid sarcoma: While granulocyte-colony stimulating factor (GCSF) has been reported to potentially cause flare-ups of MS (Openshaw et al., 2000), other series have described its use without exacerbating MS (Rossi et al., 2022), and it may offer therapeutic benefit by accelerating recovery in patients experiencing LON due to ocrelizumab.